| Patient profiles in psoriatic disease: a case-based approach. | |
| | |
MedLine Citation:
|
PMID: 18341241 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Psoriasis and psoriatic arthritis are related conditions that can have numerous untoward consequences. Moreover, appropriate management of these conditions can be challenging, as each affected patient has unique needs that must be addressed. With that in mind, the authors discuss three real-life cases, highlighting principles that may facilitate the effective case-by-case management of psoriatic disease. |
| | |
Authors:
|
Mary Wiatrowski; Nicole Furfaro |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Dermatology nursing / Dermatology Nurses' Association Volume: Suppl ISSN: 1060-3441 ISO Abbreviation: Dermatol Nurs Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2008-03-17 Completed Date: 2008-04-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9011113 Medline TA: Dermatol Nurs Country: United States |
Other Details:
|
Languages: eng Pagination: 5-19; quiz 20-1 Citation Subset: N |
Affiliation:
|
Texas Dermatology Associates' Specialty Psoriasis Clinic, Dallas, TX, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anti-Inflammatory Agents / therapeutic use* Antibodies, Monoclonal / therapeutic use Antirheumatic Agents / therapeutic use* Arthritis, Psoriatic / diagnosis, drug therapy* Female Humans Immunoglobulin G / therapeutic use Immunosuppressive Agents / therapeutic use* Male Middle Aged Receptors, Tumor Necrosis Factor / antagonists & inhibitors*, therapeutic use Recombinant Fusion Proteins / therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Receptors, Tumor Necrosis Factor; 0/Recombinant Fusion Proteins; 0/adalimumab; 0/efalizumab; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; 222535-22-0/alefacept |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Empire matters: implications for pastoral care.
Next Document: Quantitative structure-activity relationship study of ATP-sensitive potassium channel openers: deriv...